Novavax, Inc. (NASDAQ:NVAX) currently has a daily average trading volume of 8.41M but it saw 3543692 shares traded in last market. With a market cap of 635.37M USD, the company’s current market price of $4.54 came rising about 0.22 while comparing to the previous closing price of $4.53. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.36 and as low as $3.53.
Taking a look at 20-day trading activity of Novavax, Inc. (NVAX) gives us an average price of $4.98, while its current price level is -60.04% below from 52-week high level whereas it is 28.52% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $4.63 while that of 200 days or SMA-200 reads an average of $6.29. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.03% during that period while stretching the period over a month that increases to 6.42%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 43.14 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the B. Riley Securities which upgraded the stock as “Buy” in its note to investors issued on August 09, 2023, recommending a price target of $15 for it. TD Cowen downgraded its recommendation for the stock as a “Market Perform” from “Outperform” on April 20, 2023 while assigning a price target range of $55-$10. B. Riley Securities issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $29 and $10.
Over the week, NVAX’s stock price is moving -3.61% down while it is -17.30% when we observe its performance for the past one month. Year-to-date it is -5.42% down and over the past year, the stock is showing a downside performance of -34.49%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$1.44 beaten by the consensus estimate of -$0.45 for the same. For NVAX, analysts are forecasting an EPS-growth rate of 85.20% for current year and estimate for EPS growth in next year is 115.00%. In next quarter, company is expected to be making quarterly sales of $76.65 million as analysts are expecting the sales for current fiscal year at $849.66 million and seeing the company making $929.22 million in sales next year. Moreover, analysts are in estimates of $101.45 million for current-quarter revenue.
Currently, Novavax, Inc.’s total number of outstanding shares is 139.51M with 4.99% of that held by the insiders while 56.31% of its common stock has been owned by the institutions. It has a 36.81 of forward P/E ratio. Stock’s beta reads 1.61. Stock has a price to sale or P/S ratio amounts to 0.65. Its return on asset (ROA) is -26.50% on average.
